SecBot SecBot

TCRT drug pipeline

$1.60
−1.8% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
5
1 bearish · 4 neutral
Phase 3 trials
2
0 with results posted

Drugs

soonest catalyst first
▼ bearish
Impact
PhasePreclinical
Time to marketUnknown — still preclinical; IND-enabling studies not yet started; likely 5+ years away from any potential approval assuming financing and successful clinical development

ALN1003 Updated Jul 3

What to watch

ALN1003 is too early-stage to drive a catalyst-based trade. The only near-term binary is financing: watch for a dilutive equity offering or reverse split. Without a capital infusion, the company cannot fund IND-enabling studies. This is a speculative story stock, not a drug catalyst play.

Bull case
  • ALN1003 offers a differentiated non-hormonal, non-incretin oral approach to obesity, a $100B+ market dominated by injectable GLP-1 drugs, leaving room for oral alternatives with different mechanisms.
  • Mouse studies showed up to -30.5% body weight reduction (p<0.0001) and improvements in liver health markers (lower NAS scores, lower liver enzymes, reduced liver weight), suggesting potential as both a weight-loss and metabolic drug.
  • Vanguard increased its TCRT position by 43.3% in Q4 2025 and BlackRock maintained its stake through Q1 2026, indicating some institutional interest at low valuation levels.
Bear case
  • Preclinical only, ALN1003 has never been tested in humans. Non-GLP mouse data with confounders (dose aversion, dehydration in high-dose group) may not translate to human safety or efficacy.
  • Cash crisis, only ~$0.354M cash as of March 31, 2026, with runway into Q2 2026. The company will almost certainly need dilutive financing or may run out of cash entirely before advancing the program.
  • Analyst consensus is negative: 0 buy, 3 hold, 1 sell, 2 strong sell, zero bullish analyst coverage.

Fresh Drug Report

This drug report is still fresh. Subscribe to read its impact, phase, bull and bear case and thesis.

Subscribe for Full Access

Fresh Drug Report

This drug report is still fresh. Subscribe to read its impact, phase, bull and bear case and thesis.

Subscribe for Full Access

Fresh Drug Report

This drug report is still fresh. Subscribe to read its impact, phase, bull and bear case and thesis.

Subscribe for Full Access

Fresh Drug Report

This drug report is still fresh. Subscribe to read its impact, phase, bull and bear case and thesis.

Subscribe for Full Access

Other drugs in filings and trials

no drug report yet

Clinical trials

10 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
Neoantigen specific TCR-T cell drug productPhase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid TumorsPhase 2Terminated · results8Sep 30, 2023
CarboplatinStudy of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study)Phase 3Terminated188Dec 2, 2014
IndibulinStudy of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast CancerPhase 2Completed60May 1, 2013
doxorubicin in combination with palifosfamide-trisStudy of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue SarcomaPhase 3Terminated447Mar 13, 2013
Palifosfamide Tris and DoxorubicinA Study of Palifosfamide Tris Plus Doxorubicin Versus Doxorubicin in Unresectable or Metastatic Soft-tissue SarcomaPhase 2Terminated67Sep 20, 2010
DarinaparsinPhase II Study of ZIO-101 in Advanced Blood and Bone Marrow CancersPhase 2Terminated50Jun 30, 2009
indibulinPhase 1b Study of Indibulin in Combination With Capecitabine in Advanced Solid TumorsPhase 2Completed7Jun 11, 2009
DarinaparsinA Phase-II Trial of ZIO 101 in Advanced Hepatocellular CarcinomaPhase 2Terminated15Aug 9, 2008
ZIO-201Study of ZIO-201 in Advanced SarcomaPhase 2Completed53Jan 16, 2008
DarinaparsonA Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001bPhase 2Completed17Dec 21, 2007